The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast-growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

We spoke with Rob Naylor, incoming CEO  (appointment effective from 19 February 2021) to explain a bit more about the company.

Rob has 24 years’ experience in capital markets. Rob was most recently at Cenkos Securities plc as head of corporate finance and corporate broking in the investment funds team. Prior to this Rob has held roles as co-head of the investment funds team at Panmure Gordon (UK) Limited and executive director, head of product development in the investment trust team at JPMorgan Asset Management Limited.

https://www.share-talk.com/rob-naylor-incoming-ceo-intuitive-investments-group-iig-l-interview/